Skip to main content

Table 1 Comparison of the demographic and clinical findings of the oral BP and IV BP groups

From: Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment

Measurements Oral BP
Mean ± SD
IV BP
Mean ± SD
Difference
p value
Number of patients n = 251 n = 27  
Age (years) 73.2 ± 7.5 (min 40, max 90) 64.1 ± 7.7 (min 51, max 80) < .001
Sex (female, %) n = 242 (96.4%) n = 19 (70.4%) < .001*
Primary cause of BP medication
 Osteoporosis 251  
 Malignant disease 27  
 Multiple myeloma 15  
 Breast cancer 10  
 Prostate cancer 2  
BP medication
 Alendronate (weekly, oral) 141 (56.2%)  
 Risedronate (weekly, or monthly, oral) 47 (18.7%)  
 Ibandronate (monthly, oral) 36 (14.3%)  
 Used multiple oral BP 20 (8.0%)  
 Pamidronate (monthly, IV) 1 (3.7%)  
 Zolendronate (monthly, IV) 24 (88.9%)  
 Used multiple IV BP 2 (7.4%)  
Duration of medication (months) 53.1 ± 36.7 31.4 ± 20.4 .003
MRONJ clinical stage .079*
 Stage 0 9 (3.6%) 1 (3.7%)  
 Stage 1 6 (2.4%) 2 (7.4%)  
 Stage 2 84 (33.5%) 14 (51.9%)  
 Stage 3 152 (60.5%) 10 (37.0%)
  1. Inter-group differences were analyzed with independent t test; chi-squared test* was used for categorical variables